KTTA - pasitheaclinics.com Debt to Book Capitalization Ratio

Corporate company logo of Pasithea Therapeutics (KTTA)

Pasithea Therapeutics production facilities operate strictly according to clinical plans with sterile equipment calibration. The total debt-to-book capitalization ratio reflects liability dynamics, with the indicator fixed at 0.00. Business stability is ensured by the non-cyclical nature of neuropharmaceuticals, while the implementation of AI brain mapping accelerates the search for schizophrenia treatments, reducing dependence on macroeconomic factors.

Pasithea Therapeutics Corp (KTTA) - Debts to Book Value from 07/04/2022 to 10/28/2026
Product sample of Pasithea Therapeutics Corp.

Long-term investing requires strict control of debt load to minimize default risk. The specifics of drug development at Pasithea Therapeutics (KTTA) entail high binary risks and a lack of stable revenue. Historical debt-to-book capitalization dynamics reflect the proportion of liabilities relative to the issuer's equity. A low level of this ratio confirms the presence of a significant liquidity buffer. Such a balance sheet structure guarantees the financial stability of Pasithea Therapeutics (KTTA) during periods of clinical trials.

Competitors of Pasithea Therapeutics (KTTA)

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|XENE (Xenon Corp) - Debts to Book Value|Debt to Book Capitalization Ratio Viking Therapeutics VKTX|Debts to Book Capitalization Ratio supernus.com|Debts to Book Capitalization CPRX|Debts to Book Capitalization DNLI (Denali)|Debt to Book Capitalization Ratio HRMY|Debts to Net Assets Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|trevitherapeutics.com (TRVI) - Debts to Net Assets|PRAX - Debt to Book Value|Anavex (AVXL) - Debt to Book Capital|CBLL - Debts to Book Capitalization|Debt to Net Assets Ratio prothena.com|Alector, Inc. - Debts to Book Capitalization|Debts to Book Value annexonbio.com (ANNX)|Debts to Book Capitalization OMER (Omeros)|NGNE - Debts to Book Capitalization|Debt to Book Value AC Immune Corp (ACIU)|Voyager Corp (VYGR) - Debt to Net Assets Ratio|NMRA - Debt to Book Value|scilexholding.com (SCLX) - Debt to Book Capital|TVGN - Debts to Book Capitalization|Debt to Net Assets Ratio Alpha Cognition Corp|Cognition Therapeutics - Debts to Book Capitalization|Debts to Book Value IKT (Inhibikase Pharma)|Debt to Book Capitalization Ratio Cassava Sciences, Inc.|Debt to Net Assets Ratio Assertio Holdings ASRT|Coya - Debts to Book Capitalization|VTGN: Debts to Book Capitalization|Debt to Book Capitalization Ratio ovidrx.com (OVID)|Acumen Pharmaceuticals, Inc (ABOS) - Debts to Book Capitalization Ratio|Debts to Book Capitalization CRVO (CervoMed Inc.)|Debts to Book Value Alterity Therapeutics Ltd (ATHE)|Debt to Book Value CLNN|Debts to Book Capitalization pepgen.com PEPG|Debt to Book Value Jupiter Neurosciences Inc (JUNS)|Debt to Book Capital Relmada Corp RLMD|Debts to Book Capitalization ANVS (Annovis Bio, Inc.)|GRCE - Debts to Net Assets|AIFF (Firefly Neuroscience) - Debts to Book Capitalization|KLTO (Klotho Neurosciences) - Debt to Book Value|NRSN: Debt to Book Capitalization Ratio|Debts to Net Assets RVPH|Debt to Book Capitalization Ratio MTVA|Debts to Book Capitalization neuraxis.com NRXS|Debt to Book Value Helius Medical Technologies (HSDT)|PASG - Debt to Book Capital|Debt to Book Value Neuphoria NEUP|NERV - Debt to Book Capital|ATHA: Debts to Book Capitalization|ADXN (addextherapeutics.com) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Alzamend Neuro Inc. (ALZN)|Debt to Book Value Ratio Cyclerion|Protagenic Therapeutics - Debts to Book Capitalization|Debts to Book Value cortigent.com CRGT|Debt to Book Value ATXI (Avenue Therapeutics)|brainstorm-cell.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Cara Therapeutics (CARA)|CHRO: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debts to Book Value|Debt to Book Capitalization Ratio Longboard Pharmaceuticals LBPH|Debts to Book Capitalization Ratio marinuspharma.com|Debts to Book Capitalization NKGN|Debts to Book Capitalization NRBO (NeuroBo Pharmaceuticals Inc)|Debt to Book Capitalization Ratio SAGE|Debts to Net Assets Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|Vigil Neuroscience (VIGL) - Debts to Net Assets|WENA - Debt to Book Value|Cerevel Therapeutics Inc (CERE) - Debt to Book Capital